Skip to main content

Table 2 Patients’ characteristics

From: Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation

Characteristics

MFH (n = 52)

EHF (n = 30)

P

Total (n = 82)

Age, median (range)

68 (44–85)

68 (46–80)

.464

68 (44–85)

ECOG PS

 0

10 (19%)

10 (33%)

.249a)

20 (24%)

 1

41 (79%)

20 (67%)

 

61 (75%)

 2

1 (2%)

0

 

1 (1%)

Gleason score

  ≤ 6

35 (67%)

17 (57%)

.544a)

52 (63%)

 7

14 (27%)

10 (33%)

 

24 (29%)

 8–10

3 (6%)

3 (10%)

 

6 (7%)

Initial PSA (ng/ml)

  < 10

36 (69%)

19 (63%)

.203a)

55 (67%)

 10–20

12 (23%)

11 (37%)

 

23 (28%)

  > 20

4 (8%)

0 (0%)

 

4 (5%)

T stage

 T1

20 (38%)

9 (30%)

.362b)

29 (35%)

 T2

25 (48%)

19 (63%)

 

44 (54%)

 T3

7 (13%)

2 (7%)

 

9 (11%)

NCCN Risk group

 Low

21 (40%)

7 (23%)

.131b)

28 (34%)

 Intermediate

19 (37%)

18 (60%)

 

37 (45%)

 High

12 (23%)

5 (17%)

 

17 (21%)

  1. MHF moderate hypofractionation, EHF extreme hypofractionation, ECOG Eastern Cooperative Oncology Group, PS performance status, NCCN National Comprehensive Cancer Network V2 2009
  2. a)Fisher’s exact test; b) Chi-square test